Zydus gets USFDA final approval for Imatinib Mesylate Tablets

Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Imatinib Mesylate Tablets, 100 mg and 400 mg. (US RLD: Gleevec® Tablets)

This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumors of the stomach and digestive system. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, in Ahmedabad.

The group now has 285 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus gets USFDA nod for Lamotrigine Extended-Release Tablets for seizures

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Read also: Zydus gets USFDA final approval for Perphenazine Tablets USP